Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection

PLoS Pathogens

Volumn 5, Issue 9, 2009, Pages

  Moore, Penny L ^a,b   Ranchobe, Nthabeleng ^a   Lambson, Bronwen E ^a   Gray, Elin S ^a   Cave, Eleanor ^a   Abrahams, Melissa Rose ^c   Bandawe, Gama ^c   Mlisana, Koleka ^d   Abdool Karim, Salim S ^d   Williamson, Carolyn ^c   Morris, Lynn ^a,b  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; GLYCAN; NEUTRALIZING ANTIBODY; VIRUS PROTEIN; EPITOPE; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RNA;

ALPHA HELIX; AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PROTEIN TARGETING; VIRUS ENVELOPE; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; VIRUS STRAIN; CELL LINE; CHEMISTRY; GENETICS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOLECULAR GENETICS; MUTATION; PHYSIOLOGY; PROTEIN MOTIF; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODY DIVERSITY; CELL LINE; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; RNA, VIRAL; VIRUS REPLICATION;

EID: 70349686331     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000598     Document Type: Article

References (52)

1. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, et al. (2007) Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 81: 6187-6196. (Pubitemid 46878025)
2. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, et al. (2006) Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 80: 5211-5218. (Pubitemid 43752766)
3. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149. (Pubitemid 36418171)
4. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
5. Delwart EL, Pan H, Sheppard HW, Wolpert D, Neumann AU, et al. (1997) Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol 71: 7498-7508. (Pubitemid 27391690)
6. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, et al. (1990) Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4: 107-112. (Pubitemid 20108767)
7. Arendrup M, Nielsen C, Hansen JE, Pedersen C, Mathiesen L, et al. (1992) Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr 5: 303-307.
8. Bradney AP, Scheer S, Crawford JM, Buchbinder SP, Montefiori DC (1999) Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J Infect Dis 179: 1264-1267. (Pubitemid 29196512)
9. Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, et al. (2003) Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol 170: 3906-3914. (Pubitemid 36359262)
10. Tremblay M, Wainberg MA (1990) Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis 162: 735-737. (Pubitemid 20266169)
11. Geffin R, Hutto C, Andrew C, Scott GB (2003) A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. Virology 310: 207-215. (Pubitemid 37487622)
12. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H (2008) Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 82: 7932-7941.
13. Burns DP, Collignon C, Desrosiers RC (1993) Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol 67: 4104-4113. (Pubitemid 23180736)
14. Burns DP, Desrosiers RC (1991) Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol 65: 1843-1854.
15. Kinsey NE, Anderson MG, Unangst TJ, Joag SV, Narayan O, et al. (1996) Antigenic variation of SIV: mutations in V4 alter the neutralization profile. Virology 221: 14-21. (Pubitemid 26266538)
16. Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, et al. (2009) Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol 83: 662-672.
17. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, et al. (2005) Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 102: 18514-18519. (Pubitemid 43011257)
18. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, et al. (2007) Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 81: 1350-1359. (Pubitemid 46167856)
19. Sagar M, Wu X, Lee S, Overbaugh J (2006) Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80: 9586-9598. (Pubitemid 44435633)
20. Chackerian B, Rudensey LM, Overbaugh J (1997) Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 71: 7719-7727. (Pubitemid 27391717)
21. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, et al. (2008) The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 82: 1860-1869. (Pubitemid 351206934)
22. Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, et al. (2005) Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol 79: 780-790. (Pubitemid 40053861)
23. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. (Pubitemid 28289647)
24. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, et al. (2004) The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78: 5205-5215. (Pubitemid 38581472)
25. Krachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, et al. (2006) Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol 80: 7127-7135. (Pubitemid 44025209)
26. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, et al. (1995) Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 69: 5723-5733.
27. Fung MS, Sun CR, Gordon WL, Liou RS, Chang TW, et al. (1992) Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol 66: 848-856.
28. Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, et al. (1994) Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 68: 8312-8320. (Pubitemid 24362725)
29. Kayman SC, Wu Z, Revesz K, Chen H, Kopelman R, et al. (1994) Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J Virol 68: 400-410. (Pubitemid 24974644)
30. Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, et al. (2006) Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 80: 1414-1426. (Pubitemid 43134099)
31. McKeating JA, Shotton C, Cordell J, Graham S, Balfe P, et al. (1993) Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol 67: 4932-4944. (Pubitemid 23215975)
32. Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, et al. (2005) The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. J Virol 79: 6909-6917. (Pubitemid 40677322)
33. Wu L, Yang ZY, Xu L, Welcher B, Winfrey S, et al. (2006) Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. Vaccine 24: 4995-5002. (Pubitemid 43796222)
34. Laird ME, Igarashi T, Martin MA, Desrosiers RC (2008) Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J Virol 82: 11054-11065.
35. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022. (Pubitemid 38393277)
36. Teeraputon S, Louisirirojchanakul S, Auewarakul P (2005) N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies. Viral Immunol 18: 343-353. (Pubitemid 41106013)
37. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, et al. (2007) Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol 81: 4886-4891. (Pubitemid 46668687)
38. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360. (Pubitemid 34734202)
39. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, et al. (2007) Unique mutational patterns in the envelope {alpha}2 amphipathic helix and acquisition of length in gp120 hyper-variable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol 81: 5658-5668. (Pubitemid 46847005)
40. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, et al. (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265: 10373-10382. (Pubitemid 20212763)
41. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, et al. (2004) Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14: 1229-1246.
42. Zhu X, Borchers C, Bienstock RJ, Tomer KB (2000) Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39: 11194-11204.
43. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82: 12449-12463.
44. van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris L, et al. (2008) Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS ONE 3: e1954. doi: 10.1371/journal.pone.0001954. (Pubitemid 352003412)
45. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, et al. (2009) Quantitating the multiplicity of infection with HIV-1 subtype C reveals a non-Poisson distribution of transmitted variants. J Virol 83: 3556-3567.
46. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, et al. (2008) Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 82: 3952-3970.
47. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599. (Pubitemid 47236692)
48. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, et al. (1996) Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol 70: 1651-1667.
49. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L (2006) Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med 3: e255. doi: 10.1371/journal. pmed.0030255. (Pubitemid 44125988)
50. Montefiori D (2004) Evaluating neutralizing antibodies againts HIV, SIV and SHIV in luciferase reporter gene assays. In: J. E. Coligan AMK, D. H. Margulies, E. M. Shevach, W. Strober, and R. Coico, eds. Current Protocols in Immunology. New YorkNY: John Wiley & Sons. pp 12.11.11-12.11.15.
51. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557.
52. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028.